Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: Balancing methodological rigor andresearch ethics

Social Science and Medicine

Volumn 94, Issue , 2013, Pages 115-123

  Underhill, Kristen ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Behavioral disinhibition; Condom migration; HIV prevention; Placebo controlled trial; Research ethics; Risk compensation; Risk homeostasis; Study design

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO;

BEHAVIOR CHANGE; CHEMOPROPHYLAXIS; CIRCUMCISION; DECEPTION; DRUG EFFICACY; EQUIPOISE; EXTERNAL VALIDITY; HEALTH BEHAVIOR; HEALTH BELIEF; HEALTH CARE UTILIZATION; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MEDICAL ETHICS; MEDICAL TECHNOLOGY; MEDICATION COMPLIANCE; NESTED TRIAL STRATEGY; NOTE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PERCEPTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STUDY DESIGN; TWO TRIAL STRATEGY;

BEHAVIORAL DISINHIBITION; CONDOM MIGRATION; HIV PREVENTION; PLACEBO-CONTROLLED TRIAL; RESEARCH ETHICS; RISK COMPENSATION; RISK HOMEOSTASIS; STUDY DESIGN;

BIOMEDICAL TECHNOLOGY; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; ETHICS, RESEARCH; HIV INFECTIONS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; RISK-TAKING;

EID: 84881368163     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2013.03.020     Document Type: Note

References (60)

1. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV in women. Science July 19 2010, 10.1126/science.1193748.
2. Adams J. Risk 1995, University College of London Press.
3. Adams J., Hillman M. The risk compensation theory and bicycle helmets. Injury Prevention 2001, 7:343.
4. Baeten J.M., Donnell D., Ndase P., Mugo N.R., Campbell J.D., Wangisi J., et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine 2012, 367:399-410.
5. Brewer N.T., Cuite C.L., Herrington J.E., Weinstein N.D. Risk compensation and vaccination: can getting vaccinated cause people to engage in risky behaviors?. Annals of Behavioral Medicine 2007, 34:95-99.
6. Brooks R.A., Landovitz R.J., Kaplan R.L., Lieber E., Lee S.J., Barkley T.W. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care and STDs 2012, 26:87-94.
7. Carballo-Dieguez, A., Balan, I., Frasca, T., Dolezal, C., & Valladares, J. (2012). Use of a rapid HIV home test to screen potential sexual partners prevents HIV exposure in a high-risk sample of MSM. XIX International AIDS Conference (p.TUPDC0304). Washington, D.C., USA.
8. Center for HIV Identification, Prevention, and Treatment Services Preparing for PrEP: A stakeholder's dialogue 2009, 18. Atlanta, GA.
9. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine 2011, 365:493-505.
10. Council for International Organizations of Medical Sciences (CIOMS) International ethical guidelines for biomedical research involving human subjects 2002, CIOMS, Geneva, Switzerland.
11. Crosby R.A., Ricks J., Young A. Condom migration resulting from circumcision, microbicides and vaccines: brief review and methodological considerations. Sexual Health 2012, 9:96-102.
12. Desai K., Sansom S.L., Ackers M.L., Stewart S.R., Hall H.I., Hu D.J., et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008, 22:1829-1839.
13. Eaton L.A., Kalichman S.C. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Current HIV/AIDS Reports 2007, 4:165-172.
14. FDA Truvada for PrEP fact sheet: Ensuring safe and proper use 2012, US Department of Health & Human Services.
15. FDA Center for Drug Evaluation and Research. (2012). Antiviral drugs advisory committee meeting: Draft questions to the committee.
16. Fowler S.P., Williams K., Resendez R.G., Hunt K.J., Hazuda H.P., Stern M.P. Fueling the obesity epidemic? Artificially sweetened beverage use and long-term weight gain. Obesity 2008, 16:1894.
17. Gertler P., Shah M., Bertozzi S.M. Risky business: the market for unprotected commercial sex. Journal of Political Economy 2005, 113:518-550.
18. Gilead Sciences Inc Truvada: Risk evaluation and mitigation strategy 2012.
19. Glendon A.I. Areview of risk homeostasis theory in simulated environments. Safety Science 1996, 22:15.
20. Golub S.A., Kowalczyk W., Weinberger C.L., Parsons J.T. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. Journal of Acquired Immune Deficiency Syndromes 2010, 54:548-555.
21. Grady D. FDA advisory panel backs preventive use of HIV drug. The New York Times 2012, A1. New York, NY.
22. Grant R.M., Lama J.R., Anderson P.L., McMahan V., Liu A.Y., Vargas L., et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine 2010.
23. Grant, R., & McConnell, J. (2008). The trouble with risk compensation. XVII international AIDS conference (p. CDC0253). Mexico City, Mexico.
24. Hedlund J. Risky business: safety regulations, risk compensation, and individualbehavior. Injury Prevention 2000, 6:82-90.
25. Helweg-Larsen M., Shepperd J.A. Do moderators of the optimistic bias affect personal or target risk estimates? A review of the literature. Personality and Social Psychology Review 2001, 5:74-95.
26. Hogben M., Liddon N. Disinhibition and risk compensation: scope, definitions, and perspective. Sexually Transmitted Diseases 2008, 35:1009-1010.
27. Institute of Medicine Clearing the smoke: Assessing the science base for tobaccoharm reduction 2001, National Academy of Sciences, Washington, DC.
28. Jay J.S., Gostin L.O. Ethical challenges of preexposure prophylaxis for HIV. JAMA 2012, 308:867-868.
29. Kahan D. Who fears the HPV vaccine, who doesn't, and why? An experimental study of the mechanisms of cultural cognition. Law and Human Behavior 2010, 34:501.
30. Klick J., Stratmann T. Subsidizing addiction: do state health insurance mandates increase alcohol consumption?. Journal of Legal Studies 2006, 35:175.
31. Klick J., Stratmann T. Diabetes treatments and moral hazard. Journal of Law and Economics 2007, 50:519.
32. Krakower, D., Mimiaga, M., Rosenberger, J., Novak, D., Mitty, J., White, J., etal. (2012). Anticipated risk compensation with pre-exposure prophylaxis use among North American men who have sex with men using an internet social network. XIX international AIDS Conference (p. TUAC0302). Washington, D.C., USA.
33. Leibowitz A.A., Parker K.B., Rotheram-Borus M.J. AUS policy perspective on oral preexposure prophylaxis for HIV. American Journal of Public Health 2011, 101:982-985.
34. McCarthy M. The benefit of seat belt legislation in the United Kingdom. Journal of Epidemiology and Community Health 1989, 43:218-222.
35. Mackay M. Seat belts and risk compensation. BMJ 1985, 291:757-758.
36. Malani A. Identifying placebo effects with data from clinical trials. Journal of Political Economy 2006, 1:236.
37. Malani A. Regulation with placebo effects. Duke Law Journal 2008, 58:411.
38. Mascolini M. Who's prepared to make PrEP work?. Research Initiative Treatment Action 2012, 17:5-27.
39. McKenna F.P. Do safety measures really work? An examination of risk homoeostasis theory. Ergonomics 1985, 28:489-498.
40. Microbicide Trials Network MPN-003C-01 - Protocol for PREMIS: Preventive misconception in HIV prevention trials 2012.
41. Miller F.G., Joffe S. Equipoise and the dilemma of randomized clinical trials. New England Journal of Medicine 2011, 364:476-480.
42. Morrongiello B.A., Lasenby J., Walpole B. Risk compensation in children: why do children show it in reaction to wearing safety gear?. Journal of Applied Developmental Psychology 2007, 28:56-63.
43. Morrongiello B.A., Walpole B., Lasenby J. Understanding children's injury-risk behavior: wearing safety gear can lead to increased risk taking. Accident Analysis and Prevention 2007, 39:618-623.
44. National Alliance of State & Territorial AIDS Directors Pre-exposure prophylaxis (PrEP): Health department issues for consideration 2012, NASTAD.
45. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research The Belmont report 1979, U.S. Department of Health & Human Services.
46. O'Neill B., Williams A. Risk homeostasis hypothesis: a rebuttal. Injury Prevention 1998, 4:92-93.
47. Paltiel A.D., Freedberg K.A., Scott C.A., Schackman B.R., Losina E., Wang B., et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clinical Infectious Diseases 2009, 48:806-815.
48. Peltzman S. The effects of automobile safety regulation. Journal of Political Economy 1975, 83:677.
49. Peterson S., Hoffer G., Millner E. Are drivers of airbag-equipped cars more aggressive? A test of the offsetting behavior hypothesis. Journal of Law and Economics 1995, 38:251.
50. Peterson L., Taylor D., Roddy R., Belai G., Phillips P., Nanda K., et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, doubleblind, randomized, placebo-controlled trial. PLoS Clinical Trials 2007, 2:e27.
51. Schulz K.F., Altman D.G., Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:c332.
52. Siegfried N., Muller M., Deeks J.J., Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database of Systematic Reviews 2009, CD003362.
53. Streff F.M., Geller E.S. An experimental test of risk compensation: between-subject versus within-subject analyses. Accident Analysis and Prevention 1988, 20:277-287.
54. Thigpen M.C., Kebaabetswe P.M., Paxton L.A., Smith D.K., Rose C.E., Segolodi T.M., et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine 2012, 367:423-434.
55. Tripathi, A., Whiteside, Y. O., Scanlon, C., & Duffus, W. A. (2012). Perceptions and attitudes about pre-exposure prophylaxis (PrEP) among seronegative partners and potential of sexual disinhibition associated with the use of PrEP. XIX internationalAIDS conference. Washington, D.C., USA.
56. Underhill K. Preexposure chemoprophylaxis for HIV prevention. New England Journal of Medicine 2011, 364:1374. author reply 1374-1375.
57. Underhill, K. Risk-taking and rulemaking: addressing risk compensation behavior through FDA regulation of prescription drugs. Yale Journal on Regulation, 30.
58. Underhill, K., Morrow, K., Operario, D., Ducharme, R., Kuo, C., & Mayer, K. (2012). Project PrEP Talk: An in-depth qualitative analysis of PrEP acceptability, expectationsand risk compensation beliefs among United States MSM. XIX International AIDS Conference (p. TUPD0306). Washington, D.C., USA.
59. Wilde G.J.S. Target risk 2: A new psychology of safety and health 2001, PDE Publications, Toronto, Ontario.
60. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects 2008.